{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000030","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.355727+00:00","generated_at":"2026-06-04T23:08:05.913042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rallybio reports Q4 net loss $20.2M, cash $109.9M; workforce cut 45%, Phase 2 RLYB212 on track","bullets":["Net loss Q4 2023 $20.2M ($0.50/sh); full year loss $74.6M ($1.84/sh).","Cash, equivalents, marketable securities $109.9M at Dec 31, 2023; runway into mid-2026 after 45% workforce reduction.","EMA protocol assistance feedback received for RLYB212; Phase 2 FNAIT study expected to start 2H 2024.","RLYB116 Phase 1 multiple dose showed >93% free C5 reduction; manufacturing enhancements to enable higher doses.","R&D expenses $53.5M (up 31% YoY); G&A $25.4M (down 7% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000030","json":"https://secwatch.observer/filing/0001739410-24-000030.json","markdown":"https://secwatch.observer/filing/0001739410-24-000030.md","text":"https://secwatch.observer/filing/0001739410-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/0001739410-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/rlyb-20240312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:08:05.913042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64c09e7a75451b54f860247ff27aaf5c1f0a02cc","claim":"Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 12, 2024, Rallybio Corporation issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/0001739410-24-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}